MRI-Mapped Dose-Escalated Salvage Radiotherapy Post-Prostatectomy: The MAPS Trial

NAActive, not recruitingINTERVENTIONAL
Enrollment

37

Participants

Timeline

Start Date

July 12, 2012

Primary Completion Date

February 13, 2024

Study Completion Date

February 13, 2028

Conditions
Prostate CancerProstate Adenocarcinoma
Interventions
RADIATION

Standard Salvage Radiation Treatment (SSRT)

A total dose of 68 Gy delivered in 34 fractions to the Clinical Target Volume (CTV), 51 Gy in 34 fractions can be given to the pelvic nodes.

RADIATION

Mapped Tumor Salvage RT (MTSRT)

Dose escalation to the imaging or Dynamic Contrast Enhanced MRI (DCE-MRI)-defined dominant region(s) by dose painting at 2.25 Gy per fraction, while the rest of the Clinical Target Volume (CTV) receives 2.0 Gy a fraction to 68 Gy. The mapped tumor (MT) boost region will receive an absolute dose of 76.5 Gy. Assuming an α/β ratio of 3.0, this would be equivalent to 80 Gy in 2.0 Gy fractions.

Trial Locations (1)

33136

University of Miami, Miami

All Listed Sponsors
lead

University of Miami

OTHER

NCT01411345 - MRI-Mapped Dose-Escalated Salvage Radiotherapy Post-Prostatectomy: The MAPS Trial | Biotech Hunter | Biotech Hunter